Updated Edition,oral delivery

The field of medicine is constantly evolving, seeking more convenient and effective ways to administer therapeutic agents. While small molecules have long been amenable to oral delivery, the oral delivery of peptides and proteins has remained a significant hurdle. These complex biomolecules, crucial for treating a wide range of diseases from diabetes to cancer, have traditionally required injectable or subcutaneous administration, often leading to patient discomfort and reduced adherence to treatment regimens. However, recent advancements are paving the way for a new era where peptide and protein drugs (PPDs) can be effectively delivered through the oral route, offering immense benefits for patients and healthcare systems alike.

Historically, the gastrointestinal (GI) tract has been a formidable barrier to the oral delivery of proteins and peptides. The very nature of our digestive system is designed to efficiently break down a wide variety of dietary proteins and peptides into absorbable amino acids. This enzymatic degradation, coupled with the harsh acidic environment of the stomach and the varying pH levels throughout the GI tract, poses significant challenges. Furthermore, the intestinal epithelium itself presents a barrier to the passage of these larger molecules. As highlighted in numerous studies, peptides with short half-lives are not merely complex to deliver orally; they are pharmacokinetically incompatible with the oral route without specialized strategies.

Despite these inherent difficulties, the allure of oral peptide delivery is undeniable. The convenience for patients, promoting better adherence to dosing regimens than injections, is a primary driver. The potential to bypass the need for needles and improve patient quality of life is substantial. This pursuit has led to extensive research into overcoming the oral peptide delivery challenges and exploring innovative delivery methods.

Barriers and Breakthroughs in Oral Peptide and Protein Delivery

The oral delivery of therapeutic proteins and peptides faces several key obstacles:

* Enzymatic Degradation: The GI tract is rich in proteases and peptidases, such as pepsin in the stomach and trypsin and chymotrypsin in the small intestine, which rapidly break down proteins and peptides. As noted, there are many enzymatic barriers to the oral delivery of PPs, involving various digestive enzymes throughout the GI tract.

* Acidic Environment: The stomach's highly acidic pH (around 1.5-3.5) can denature and inactivate many proteins and peptides.

* Poor Permeability: The intestinal epithelial barrier, designed to absorb nutrients efficiently, is less permeable to large biomolecules like peptides and proteins. This results in low bioavailability, meaning only a small fraction of the administered dose reaches the bloodstream.

* First-Pass Metabolism: Even if a peptide or protein manages to cross the intestinal barrier, it is subjected to hepatic metabolism, further reducing its systemic concentration.

To circumvent these challenges, researchers have developed a variety of sophisticated strategies. These include:

* Protease Inhibitors: Co-administration of oral agents that inhibit digestive enzymes can protect peptides and proteins from degradation.

* Permeation Enhancers: These compounds temporarily increase the permeability of the intestinal epithelium, allowing larger molecules to pass through.

* Nanocarrier-Based Approaches: This has been a focal point of research, with recent aspects and patents on oral delivery of therapeutic proteins and peptides emphasizing the role of nano-carriers. These include:

* Lipid-Based Nanocarriers: Lipid-based technology can significantly aid in the oral delivery of peptides. Formulations such as liposomes, solid lipid nanoparticles (SLNs), and self-emulsifying drug delivery systems (SEDDS) can encapsulate peptides and proteins, protecting them from degradation and facilitating their absorption. As the review by Haddadzadegan et al. indicates, progress has been made on lipid-based nanocarriers in order to improve oral peptide and protein delivery.

* Polymer-Based Nanocarriers: Biodegradable polymers can be used to create nanoparticles, micelles, or hydrogels that encapsulate the therapeutic agent. These can be designed to release their payload in a controlled manner and in specific regions of the GI tract.

* Inclusion Complexes: Cyclodextrins, for example, can form complexes with peptides and proteins, shielding them from enzymatic attack and improving their solubility.

* Prodrug Strategies: Modifying the peptide or protein to create a more stable and absorbable prodrug that is then converted back to its active form in the body.

* Systemic Approaches: Novel approaches are being developed for systemic delivery, with examples including the investigation of insulin glargine, teriparatide, liraglutide, leuprolide as model drugs for innovative oral delivery of peptide formulations.

The Future Landscape of Oral Protein and Peptide Therapeutics

The continued development of these innovative delivery systems holds immense promise for the future of medicine. Oral delivery of peptides and proteins (PPs) can be considered the need of the hour due to the immense benefits of this route. While **very